Reliable Quality

Affordable Innovation

Research Progress

In addition to 4 products launched commercially and 3 NDAs accepted for review, Henlius has conducted over 20 clinical studies for 11 products and 8 immuno-oncology combination therapies worldwide. 汉利康® (rituximab injection), the first product of Henlius, has been approved by the National Medical Products Administration (NMPA) as China's first biosimilar. The second product 汉曲优® (trastuzumab, Zercepac® in the EU) is the first Chinese mAb biosimilar approved both in the EU and China, bringing more treatment options to patients with HER2 positive breast and gastric cancer worldwide. HLX01 (rituximab injection) indicated for rheumatoid arthritis, HLX04 (bevacizumab injection) and HLX10 (serplulimab injection) were accepted for NDA review by the NMPA.

Products in R&D
Target
Generic Name
Study Phase
Potential Indication
Study Phase
Product Pipeline

With the efficient and innovative in-house capabilities, Henlius has developed a diversified and advanced drug pipeline with a focus in the fields of oncology, autoimmune diseases etc.